Italia markets closed

Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)

Milan - Milan Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
51,20+0,40 (+0,79%)
Alla chiusura: 05:35PM CEST

Recordati Industria Chimica e Farmaceutica S.p.A.

Via Matteo Civitali,1
Milan, MI 20148
Italy
39 02 487871
https://www.recordati.com

Settore/iHealthcare
SettoreDrug Manufacturers - General
Impiegati a tempo pieno4.455

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Robert Koremans M.D.CEO & Director1,81MN/D1962
Mr. Luigi Felice La CorteGroup CFO & Executive Director948kN/D1969
Ms. Cathrin PettyExecutive DirectorN/DN/D1973
Mr. Giampiero MazzaExecutive DirectorN/DN/D1969
Mr. Giorgio De PalmaExecutive DirectorN/DN/D1974
Ms. Eugenia LitzVP & Head of Investor RelationsN/DN/DN/D
Ms. Bibianne BonGroup Chief Legal OfficerN/DN/DN/D
Ms. Laura ContiGroup Communications DirectorN/DN/DN/D
Mr. Gabriele FinziExecutive VP of Corporate Development, Licensing & InnovationN/DN/DN/D
Ms. Alessandra AbateGroup Chief People & Culture OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Governance aziendale

L'ISS Governance QualityScore di Recordati Industria Chimica e Farmaceutica S.p.A. al 1 maggio 2024 è 5. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.